MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:30Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:5-HT3 antagonists]]
			[[Category:Antiemetics]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #53

2026-05-23T03:34:50Z

parser-claude batch MedTemplate pre-fill, Top 300 #53

New page

{{MedTemplate
| generic = Ondansetron
| brand = Zofran, Zofran ODT
| structure =
| classes = [[:Category:5-HT3_antagonists|5-HT3 receptor antagonist]], [[:Category:Antiemetics|Antiemetic]]
| uses = <vote slug="cinv-use">Chemotherapy-induced nausea and vomiting</vote>, <vote slug="ponv-use">Postoperative nausea and vomiting</vote>, <vote slug="rinv-use">Radiation-induced nausea and vomiting</vote>, <vote slug="gastroenteritis-pediatric-use">Acute gastroenteritis in children (off-label)</vote>
| starting_dose = 4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention
| preparations = 4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL)
| fda_max = Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided
| pill_id =
| routes = Oral, IV, IM
| onset = 30 minutes PO; minutes IV
| duration = 4-12 hours
| halflife = 3-6 hours (longer in hepatic impairment)<ref name="zofran-label">FDA Prescribing Information, Zofran (ondansetron), Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020007s050,020403s019lbl.pdf</ref>
| bioavailability = ~60% (oral)<ref name="zofran-label" />
| pregnancy = Widely used for hyperemesis gravidarum; meta-analyses show a small absolute signal for orofacial clefts and possible cardiac defects but the absolute risk is low and benefit usually outweighs.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="ondansetron-mech-claim">Ondansetron is a selective antagonist of the 5-HT3 (serotonin type 3) receptor on vagal afferents in the gut and on chemoreceptor trigger zone neurons in the area postrema, blocking the serotonin-driven emetogenic signaling that follows chemotherapy, abdominal surgery, and radiation.</vote> Dose-dependent QT-interval prolongation is the principal class safety concern, driving the FDA limit on single doses<ref name="zofran-label" />. CYP3A4, CYP2D6, and CYP1A2 metabolism; ultra-rapid CYP2D6 metabolizers may have reduced efficacy, an actionable PGx consideration<ref name="cpic-ondansetron-cyp2d6">CPIC Guideline for CYP2D6 and Ondansetron / Tropisetron, 2017. https://cpicpgx.org/guidelines/cpic-guideline-for-ondansetron-and-tropisetron-and-cyp2d6/</ref>.
}}

== References ==
<references />

Ondansetron - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #53